Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 48,300 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 48,300 shares of the firm’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Anish Patel also recently made the following trade(s):

• On Monday, December 8th, Anish Patel sold 6,663 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.02, for a total value of $140,056.26.
• On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $17.40, for a total value of $116,005.80.

Enliven Therapeutics Trading Up 2.9%

Shares of ELVN traded up $0.72 during trading hours on Tuesday, reaching $25.75. 1,034,211 shares of the company’s stock traded hands, compared to its average volume of 2,488,710. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $29.98. The stock has a market cap of $1.53 billion, a PE ratio of -13.99 and a beta of 0.41. The firm’s 50 day simple moving average is $19.17 and its 200-day simple moving average is $19.97.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Key Stories Impacting Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: Technical/momentum signal — media coverage flagged rising relative price strength for ELVN, which can attract momentum traders and short‑term inflows. Read More.
• Positive Sentiment: Recent quarterly print beat expectations (reported ($0.32) vs. consensus ($0.43) in Nov.), which remains a constructive fundamental datapoint cited in coverage and analyst models. Read More.
• Neutral Sentiment: Upcoming clinical-data catalyst — analysts and commentators note Enliven is entering 2026 with planned data readouts; that creates event-driven upside but also keeps some investors cautious until results arrive. Read More.
• Neutral Sentiment: Short-interest reporting showed an anomalous zero reading as of Jan 12, which provides no clear bearish or bullish signal and is likely noise rather than an explanatory factor for today’s move.
• Negative Sentiment: Significant insider selling — CEO/insider Joseph P. Lyssikatos sold large blocks across Jan 8–9 (multiple Form 4s totaling ~132k shares across filings) and Director Richard Heyman also sold on Jan 8–9; these sales reduced insider stakes and represent material supply that can weigh on sentiment. SEC filings: Read More. and Read More.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. BNP Paribas Financial Markets grew its holdings in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. AlphaQuest LLC purchased a new position in Enliven Therapeutics during the 3rd quarter valued at about $96,000. Tower Research Capital LLC TRC raised its position in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after purchasing an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its holdings in Enliven Therapeutics by 58.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after buying an additional 2,500 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.